|
No
|
Year
|
Author
|
Age at breast cancer diagnosis
|
Mutation
|
Surveillance period (month)
|
Times of MRI surveillance
|
MRI findings
|
MRI-targeted US findings
|
Stage
|
|---|
|
1
|
2021
|
Our Case 1
|
27
|
BRCA1
|
39
|
4
|
Mass
|
Dilated duct collection
|
pT1bN0M0 StageI
|
|
2
|
2021
|
Our Case 2
|
43
|
BRCA2
|
86
|
8
|
Non-mass
|
Distortion
|
pT1bN1M0 StageIIA
|
|
3
|
2021
|
Our Case 3
|
43
|
BRCA2
|
0
|
1
|
Mass
|
Mass
|
pT1miN0M0 StageI
|
|
4
|
2021
|
Our Case 4
|
53
|
BRCA2
|
42
|
3
|
Mass
|
Mass
|
pT1bN0M0 StageI
|
|
5
|
2019
|
Shimada [6]
|
35
|
BRCA1
|
145
|
1
|
Non-mass
|
N/A
|
pTisN0M0 Stage0
|
|
6
|
2019
|
Shimada [6]
|
48
|
BRCA2
|
51
|
1
|
Non-mass
|
N/A
|
pTisN0M0 Stage0
|
|
7
|
2019
|
Murakami [7]
|
N/A
|
BRCA1
|
N/A
|
1
|
Mass
|
Visible lesion
|
N/A
|
|
8
|
2017
|
Tozaki [8]
|
48
|
BRCA2
|
N/A
|
N/A
|
Non-mass
|
hypoechoic area
|
pTisN0M0 Stage0
|
- MRI magnetic resonance imaging, US ultrasonography, N/A not applicable
